A new roadmap for preclinical and clinical trials
investigating compounds to treat and prevent Parkinson’s disease was proposed
by a team of international academic and industry researchers, the Alpha-Synuclein
Clinical Path Working Group, in conjunction with the Michael J. Fox Foundation
for Parkinson’s Research.
The article, “A Proposed Roadmap for Parkinson’s Disease
Proof of Concept Clinical Trials Investigating Compounds Targeting
Alpha-Synuclein,” was published in the Journal of Parkinson’s Disease.
A global effort is underway to find interventional molecules
that slow or stop Parkinson’s progression. These potential therapeutics focus
on targeting the protein alpha-synuclein, a component of abnormal clumps — Lewy
bodies — that are the pathological hallmark of Parkinson’s disease.
“With alpha-synuclein undoubtedly playing some role in
Parkinson’s disease pathogenesis, and there being such a diverse portfolio of
experimental therapies that target the protein, one can be optimistic and hope
that one of the approaches will eventually be successful in slowing disease
progression,” Patrik Brundin, MD, PhD, from the Van Andel Research Institute,
Grand Rapids, Michigan, said in a press release.
In 2017, The Michael J. Fox Foundation convened the
Alpha-Synuclein Clinical Path Working Group, made up of leaders in Parkinson’s
research from academia and industry. This international group set out to
expedite the discovery and development of therapeutics with recommendations on
research and development for alpha-synuclein targeting therapies.
No comments:
Post a Comment